Shield Therapeutics plc (LON:STX – Get Free Report) reached a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 3.70 and last traded at GBX 3.80, with a volume of 1146595 shares traded. The stock had previously closed at GBX 3.85.
Shield Therapeutics Trading Down 1.3%
The stock has a 50 day moving average of GBX 5.88 and a 200 day moving average of GBX 7.76. The company has a debt-to-equity ratio of -199.87, a current ratio of 0.90 and a quick ratio of 2.16. The firm has a market cap of £40.64 million, a P/E ratio of -1.90 and a beta of 1.76.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Recommended Stories
- Five stocks we like better than Shield Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
